Entering text into the input field will update the search result below

Cytori Therapeutics (CYTX), Clinical Experience shows No Increased Risk

Jan. 24, 2011 1:19 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Special Situations, Contrarian

Seeking Alpha Analyst Since 2009

Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.

No evidence of increased risk of development, metastasis or recurrence of breast cancer in contrast to laboratory data says published clinical experience in over 2,000 patients who received autologous fat grafts.

  • This includes procedures in which the graft has been enriched with adipose-derived stem and regenerative cells (ADRCs).

A newly published review entitled “Oncologic Risks of Autologous Fat Grafting to the Breast” in the January issue of the American Society of Aesthetic Plastic Surgery’s Aesthetic Surgery Journal discusses the data disparity between the clinical and certain laboratory-based scientific literature regarding fat grafting procedures to the breast.

  • The article, authored by John Fraser, Ph.D. and Marc Hedrick, M.D. of Cytori Therapeutics and Steve Cohen, MD evaluates the theoretical concerns raised by fat grafting procedures to the breast (particularly in women who have undergone treatment for breast cancer);
  • This analysis is consistent with Cytori preclinical studies, demonstrating that cell-enriched fat grafting did not increase the risk of breast cancer development or metastasis and in some situations, actually decreased cancer growth.

The article explores potential issues and concludes that the apparent data discrepancy between the laboratory and the clinic are the result of the application of artificial conditions used in certain laboratory studies that do not arise in a clinical setting.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.